schliessen

Filtern

 

Bibliotheken

Population Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate Cancer

Although the palliative benefits of hormonal therapy for metastatic prostate cancer are widely recognized, little information is available regarding the effect of hormonal therapy on cancer specific and overall survival, and the types of patients who might benefit the most or least from hormonal the... Full description

Journal Title: The Journal of Urology 2007, Vol.177(2), pp.535-539
Main Author: Lu-Yao, Grace
Other Authors: Moore, Dirk F , Oleynick, John U , Dipaola, Robert S , Yao, Siu-Long
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0022-5347 ; E-ISSN: 1527-3792 ; DOI: 10.1016/j.juro.2006.09.049
Link: https://www.sciencedirect.com/science/article/pii/S002253470602492X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_juro_2006_09_049
title: Population Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate Cancer
format: Article
creator:
  • Lu-Yao, Grace
  • Moore, Dirk F
  • Oleynick, John U
  • Dipaola, Robert S
  • Yao, Siu-Long
subjects:
  • Prostate
  • Prostatic Neoplasms
  • Medicare
  • Seer Program
  • Antineoplastic Agents
  • Hormonal
  • Medicine
ispartof: The Journal of Urology, 2007, Vol.177(2), pp.535-539
description: Although the palliative benefits of hormonal therapy for metastatic prostate cancer are widely recognized, little information is available regarding the effect of hormonal therapy on cancer specific and overall survival, and the types of patients who might benefit the most or least from hormonal therapy. Prostate cancer specific and overall survival according to hormonal therapy use was determined by the Kaplan-Meier method in 6,098 men 65 years or older diagnosed with metastatic prostate cancer in 1991 to 1999 who were identified through the population based Surveillance, Epidemiology, and End Results, and Medicare linked database. Cox proportional hazards and propensity score methods were used to adjust for potential confounders, such as disease status and patient comorbidity. Propensity score adjusted median overall survival was 26 months in men who received hormonal therapy compared with 13 months in those who did not (HR 0.66, 95% CI...
language: eng
source:
identifier: ISSN: 0022-5347 ; E-ISSN: 1527-3792 ; DOI: 10.1016/j.juro.2006.09.049
fulltext: fulltext
issn:
  • 0022-5347
  • 00225347
  • 1527-3792
  • 15273792
url: Link


@attributes
ID1882584286
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_juro_2006_09_049
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_juro_2006_09_049
sourcesystemPC
dbid
0--K
11B1
21P~
3457
44G.
57-5
6AAEDT
7AAQFI
8ADPAM
9AEVXI
10AGHFR
11AITUG
12ALXNB
13BELOY
14FDB
15FGOYB
16GBLVA
17KOM
18R2-
19RPZ
20SEL
21SES
22SSZ
23UV1
24XH2
pqid68428209
galeid161256182
display
typearticle
titlePopulation Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate Cancer
creatorLu-Yao, Grace ; Moore, Dirk F ; Oleynick, John U ; Dipaola, Robert S ; Yao, Siu-Long
ispartofThe Journal of Urology, 2007, Vol.177(2), pp.535-539
identifier
subjectProstate ; Prostatic Neoplasms ; Medicare ; Seer Program ; Antineoplastic Agents ; Hormonal ; Medicine
descriptionAlthough the palliative benefits of hormonal therapy for metastatic prostate cancer are widely recognized, little information is available regarding the effect of hormonal therapy on cancer specific and overall survival, and the types of patients who might benefit the most or least from hormonal therapy. Prostate cancer specific and overall survival according to hormonal therapy use was determined by the Kaplan-Meier method in 6,098 men 65 years or older diagnosed with metastatic prostate cancer in 1991 to 1999 who were identified through the population based Surveillance, Epidemiology, and End Results, and Medicare linked database. Cox proportional hazards and propensity score methods were used to adjust for potential confounders, such as disease status and patient comorbidity. Propensity score adjusted median overall survival was 26 months in men who received hormonal therapy compared with 13 months in those who did not (HR 0.66, 95% CI...
languageeng
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S002253470602492X$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Lu-Yao, Grace
1Moore, Dirk F
2Oleynick, John U
3Dipaola, Robert S
4Yao, Siu-Long
titlePopulation Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate Cancer
description

Although the palliative benefits of hormonal therapy for metastatic prostate cancer are widely recognized, little information is available regarding the effect of hormonal therapy on cancer specific and overall survival, and the types of patients who might benefit the most or least from hormonal therapy.

Prostate cancer specific and overall survival according to hormonal therapy use was determined by the Kaplan-Meier method in 6,098 men 65 years or older diagnosed with metastatic prostate cancer in 1991 to 1999 who were identified through the population based Surveillance, Epidemiology, and End Results, and Medicare linked database. Cox proportional hazards and propensity score methods were used to adjust for potential confounders, such as disease status and patient comorbidity.

Propensity score adjusted median overall survival was 26 months in men who received hormonal therapy compared with 13 months in those who did not (HR 0.66, 95% CI...

subject
0Prostate
1Prostatic Neoplasms
2Medicare
3Seer Program
4Antineoplastic Agents
5Hormonal
6Medicine
general
0English
1Elsevier Inc
210.1016/j.juro.2006.09.049
3ScienceDirect (Elsevier)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_juro_2006_09_049
issn
00022-5347
100225347
21527-3792
315273792
rsrctypearticle
creationdate2007
addtitleThe Journal of Urology
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
11B1
21P~
3457
44G.
57-5
6AAEDT
7AAQFI
8ADPAM
9AEVXI
10AGHFR
11AITUG
12ALXNB
13BELOY
14FDB
15FGOYB
16GBLVA
17KOM
18R2-
19RPZ
20SEL
21SES
22SSZ
23UV1
24XH2
startdate20070101
enddate20071231
lsr40The Journal of Urology, 2007, Vol.177 (2), pp.535-539
doi10.1016/j.juro.2006.09.049
citationpf 535 pt 539 vol 177 issue 2
lsr30VSR-Enriched:[galeid, pqid]
sort
titlePopulation Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate Cancer
authorLu-Yao, Grace ; Moore, Dirk F ; Oleynick, John U ; Dipaola, Robert S ; Yao, Siu-Long
creationdate20070000
lso0120070000
facets
frbrgroupid4615792415902408528
frbrtype5
newrecords20190904
languageeng
topic
0Prostate
1Prostatic Neoplasms
2Medicare
3Seer Program
4Antineoplastic Agents
5Hormonal
6Medicine
collectionScienceDirect (Elsevier)
prefilterarticles
rsrctypearticles
creatorcontrib
0Lu-Yao, Grace
1Moore, Dirk F
2Oleynick, John U
3Dipaola, Robert S
4Yao, Siu-Long
jtitleJournal of Urology
creationdate2007
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Lu-Yao
1Moore
2Oleynick
3Dipaola
4Yao
aufirst
0Grace
1Dirk F
2John U
3Robert S
4Siu-Long
auinitG
auinit1G
au
0Lu-Yao, Grace
1Moore, Dirk F
2Oleynick, John U
3Dipaola, Robert S
4Yao, Siu-Long
atitlePopulation Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate Cancer
jtitleThe Journal of Urology
date2007
risdate2007
volume177
issue2
spage535
epage539
pages535-539
issn0022-5347
eissn1527-3792
formatjournal
genrearticle
ristypeJOUR
abstract

Although the palliative benefits of hormonal therapy for metastatic prostate cancer are widely recognized, little information is available regarding the effect of hormonal therapy on cancer specific and overall survival, and the types of patients who might benefit the most or least from hormonal therapy.

Prostate cancer specific and overall survival according to hormonal therapy use was determined by the Kaplan-Meier method in 6,098 men 65 years or older diagnosed with metastatic prostate cancer in 1991 to 1999 who were identified through the population based Surveillance, Epidemiology, and End Results, and Medicare linked database. Cox proportional hazards and propensity score methods were used to adjust for potential confounders, such as disease status and patient comorbidity.

Propensity score adjusted median overall survival was 26 months in men who received hormonal therapy compared with 13 months in those who did not (HR 0.66, 95% CI...

pubElsevier Inc
doi10.1016/j.juro.2006.09.049
lad01The Journal of Urology